Newsfeed

Bei diesem Bereich handelt es sich um eine mögliche Darstellungsform der Integration von Nachrichtenquellen mit Bezug zu börsennotierten Unternehmen.
Als Präsentationsebene fungiert ein Template, dass an Kurznachrichtenservices angelehnt ist, bei dem sich Nutzer einen schnellen Überblick über aktuelle Nachrichten verschaffen können. Die Detailansichten ermöglichen bei Interesse weitergehende Recherchen.

Dieser Newsfeed ist eine Zusammenstellung aktueller Nachrichten, die aus Direktanbindungen von TopTier NewsWire-Services mit Bezug zu börsennotierten Unternehmen stammen. Dieser Feed hier dient ausschließlich Demonstrationszwecken. Sektoren-spezifische Nachrichten, Public Relations sowie Produktinformationen können über die GICS Portale > Bereich Sektor-Intelligence abgerufen werden.

US21217B1008
Filter zurücksetzen
Do you already know our new terminal view? Click here.
FIGI: BBG01M27SVP6
CTNM
Contineum Therapeutics, Inc.
GICS: Health Care · SECTOR: EQTY · SUB-SECTOR: - · THEMEFOLIO: $HLTH
NAME
Contineum Therapeutics, Inc.
ISIN
US21217B1008
TICKER
CTNM
MIC
XNAS
REUTERS
CTNM.OQ
BLOOMBERG
CTNM US
Di., 03.11.2026       Contineum Therapeutics
US21217B1008

Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated small molecule therapies for inflammatory and fibrotic diseases with significant unmet need, today reported its third-quarter 2026 financial results. “Lysophosphatidic acid 1 receptor (LPAR1) antagonism as...
Zur Nachricht
Contineum Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 29.10.2026       Contineum Therapeutics
US21217B1008

Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated small molecule therapies for inflammatory and fibrotic diseases with significant unmet need, today announced that management is scheduled to present at the Stifel 2026 Healthcare Conference on Thursday, Novem...
Zur Nachricht
Contineum Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 14.09.2026       Contineum Therapeutics
US21217B1008

Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated small molecule therapies for inflammatory and fibrotic diseases with significant unmet need, today announced that the MOONLIGHT-1 trial did not achieve its primary efficacy endpoint. The trial evaluated impro...
Zur Nachricht
Contineum Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 25.08.2026       Contineum Therapeutics
US21217B1008

Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated small molecule therapies for inflammatory and fibrotic diseases with significant unmet need, today announced that management is scheduled to present at the 2026 Morgan Stanley Global Healthcare Conference on...
Zur Nachricht
Contineum Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 30.07.2026       Contineum Therapeutics
US21217B1008

Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated small molecule therapies for inflammatory and fibrotic diseases with significant unmet need, today reported its second-quarter 2026 financial results and affirmed its key clinical development milestones. “W...
Zur Nachricht
Contineum Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 30.06.2026       Contineum Therapeutics
US21217B1008

Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced the publication of a manuscript describing the discovery and characterization of PIPE-791 in the...
Zur Nachricht
Contineum Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 01.06.2026       Contineum Therapeutics
US21217B1008

Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced that management is scheduled to present at the 2026 Goldman Sachs Global Healthcare Conference...
Zur Nachricht
Contineum Therapeutics
Charts & Research Termsheets Terminal
Permalink
Fr., 15.05.2026       Contineum Therapeutics
US21217B1008

Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced that on May 14, 2026 (Grant Date), the Compensation Committee of the Company’s Board of Directo...
Zur Nachricht
Contineum Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 12.05.2026       Contineum Therapeutics
US21217B1008

Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced that management is scheduled to present at the 2026 RBC Capital Markets Global Healthcare Confe...
Zur Nachricht
Contineum Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 11.05.2026       Contineum Therapeutics
US21217B1008

Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced two scientific posters for its lead investigational drug candidate, PIPE-791, at the upcoming A...
Zur Nachricht
Contineum Therapeutics
Charts & Research Termsheets Terminal
Permalink
Silent Ad
Di., 05.05.2026       Contineum Therapeutics
US21217B1008

Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today reported its first-quarter 2026 financial results and affirmed its key clinical development milestones....
Zur Nachricht
Contineum Therapeutics
Charts & Research Termsheets Terminal
Permalink
Fr., 01.05.2026       Contineum Therapeutics
US21217B1008

Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced that the Compensation Committee of its Board of Directors granted inducement awards to two new...
Zur Nachricht
Contineum Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 30.04.2026       Contineum Therapeutics
US21217B1008

Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today reported positive topline data from its exploratory Phase 1b trial of PIPE-791, a potentially best-in-cla...
Zur Nachricht
Contineum Therapeutics
Charts & Research Termsheets Terminal
Permalink
Fr., 13.03.2026       Contineum Therapeutics
US21217B1008

Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced that on March 12, 2026 (Grant Date), the Compensation Committee of the Company’s Board of Direc...
Zur Nachricht
Contineum Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 05.03.2026       Contineum Therapeutics
US21217B1008

Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today reported its fourth-quarter 2025 financial results and affirmed its key clinical development milestones....
Zur Nachricht
Contineum Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 03.03.2026       Contineum Therapeutics
US21217B1008

Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced that management is scheduled to present at the 2026 Leerink Partners Global Healthcare Conferen...
Zur Nachricht
Contineum Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 18.02.2026       Contineum Therapeutics
US21217B1008

Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced that on February 17, 2026 (Grant Date), the Compensation Committee of the Company’s Board of Di...
Zur Nachricht
Contineum Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 28.01.2026       Contineum Therapeutics
US21217B1008

Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced that on January 26, 2026 (Grant Date), the Compensation Committee of the Company’s Board of Dir...
Zur Nachricht
Contineum Therapeutics
Charts & Research Termsheets Terminal
Permalink
Fr., 12.12.2025       Contineum Therapeutics
US21217B1008

Contineum Therapeutics, Inc. (Nasdaq: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced the pricing of an upsized underwritten public offering of 7,346,938 shares of its Class A commo...
Zur Nachricht
Contineum Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 11.12.2025       Contineum Therapeutics
US21217B1008

Contineum Therapeutics, Inc. (Nasdaq: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced the commencement of an underwritten public offering of $75.0 million of shares of its Class A c...
Zur Nachricht
Contineum Therapeutics
Charts & Research Termsheets Terminal
Permalink
Silent Ad
Mo., 24.11.2025       Contineum Therapeutics
US21217B1008

Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced that management is scheduled to participate in a fireside chat at the 8th Annual Evercore Healt...
Zur Nachricht
Contineum Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 20.11.2025       Contineum Therapeutics
US21217B1008

Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today reported topline data from its Phase 2 VISTA trial of PIPE-307, an M1 receptor antagonist, in development...
Zur Nachricht
Contineum Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 30.10.2025       Contineum Therapeutics
US21217B1008

Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today reported its third-quarter 2025 financial results and affirmed its key clinical development milestones....
Zur Nachricht
Contineum Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 18.09.2025       Contineum Therapeutics
US21217B1008

Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced positive topline data from its PIPE-791 Phase 1b positron emission tomography (PET) trial. The...
Zur Nachricht
Contineum Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 28.08.2025       Contineum Therapeutics
US21217B1008

Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced that management is scheduled to present at the following investor conferences in September. C...
Zur Nachricht
Contineum Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 25.06.2025       Contineum Therapeutics
US21217B1008

Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced an update on its Phase 1b positron emission tomography (PET) trial of PIPE-791, a selective ant...
Zur Nachricht
Contineum Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 15.05.2025       Contineum Therapeutics
US21217B1008

Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced that management is scheduled to present at the 2025 RBC Capital Markets Global Healthcare Confe...
Zur Nachricht
Contineum Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 14.05.2025       Contineum Therapeutics
US21217B1008

Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today reported its first-quarter 2025 financial results and affirmed its key clinical development milestones....
Zur Nachricht
Contineum Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 28.04.2025       Contineum Therapeutics
US21217B1008

Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced the appointment of Timothy Watkins, M.D., M.Sc., to the Company’s executive team as its Chief M...
Zur Nachricht
Contineum Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 12.03.2025       Contineum Therapeutics
US21217B1008

Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced that management is scheduled to present at the Stifel 2025 Virtual CNS Forum on Tuesday, March...
Zur Nachricht
Contineum Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 06.03.2025       Contineum Therapeutics
US21217B1008

Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today reported its fourth-quarter 2024 financial results and affirmed its key clinical development milestones....
Zur Nachricht
Contineum Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 04.03.2025       Contineum Therapeutics
US21217B1008

Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today initiated patient dosing in its exploratory PIPE-791 Phase 1b, randomized, double-blind, placebo-controll...
Zur Nachricht
Contineum Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 03.03.2025       Contineum Therapeutics
US21217B1008

Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced that management is scheduled to present at the 2025 Leerink Partners Global Healthcare Conferen...
Zur Nachricht
Contineum Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 08.01.2025       Contineum Therapeutics
US21217B1008

Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced that it has completed the targeted enrollment of 168 patients in its Phase 2 PIPE-307 VISTA tri...
Zur Nachricht
Contineum Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 16.12.2024       Contineum Therapeutics
US21217B1008

Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments in the treatment of neuroscience, inflammation and immunology (NI&I) indicati...
Zur Nachricht
Contineum Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 25.11.2024       Contineum Therapeutics
US21217B1008

Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments in the treatment of neuroscience, inflammation and immunology (NI&I) indicati...
Zur Nachricht
Contineum Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 18.11.2024       Contineum Therapeutics
US21217B1008

Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments in the treatment of neuroscience, inflammation and immunology (NI&I) indicati...
Zur Nachricht
Contineum Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 13.11.2024       Contineum Therapeutics
US21217B1008

Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments in the treatment of neuroscience, inflammation and immunology (NI&I) indicati...
Zur Nachricht
Contineum Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 06.11.2024       Contineum Therapeutics
US21217B1008

Contineum Therapeutics, Inc. (Nasdaq: CTNM), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments in the treatment of neuroscience, inflammation and immunology (NI&I) indications, today reported financi...
Zur Nachricht
Contineum Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 28.08.2024       Contineum Therapeutics
US21217B1008

Contineum Therapeutics, Inc. (Nasdaq: CTNM), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced parti...
Zur Nachricht
Contineum Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 13.08.2024       Contineum Therapeutics
US21217B1008

Contineum Therapeutics, Inc. (Nasdaq: CTNM), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments in the treatment of neuroscience, inflammation and immunology (NI&I) indications, today reported financi...
Zur Nachricht
Contineum Therapeutics
Charts & Research Termsheets Terminal
Permalink